Antibodies News and Research

RSS

Study may help develop multi-pronged HIV eradication strategies

A team of researchers from the University of California - Davis Health (UC Davis) has made a breakthrough discovery of a unique type of stem cell that reduces the amount of the virus that causes AIDS.

From The University of California, Davis 25 Jun 2021

New methodology assesses whole-genome sequencing data of SARS-CoV-2 mutations

According to researchers from Harvard T.H. Chan School of Public Health and MIT, the use of genome-wide association studies (GWAS) methodology to assess whole-genome sequencing data of SARS-CoV-2 mutations and COVID-19 mortality data can help identify highly pathogenic variants of the virus that should be flagged for containment.

25 Jun 2021

New nanobodies could fight against SARS-CoV-2 variants

Looking for a new strategy in the long-running battle against the SARS-CoV-2 virus, researchers have developed nanobodies.

23 Jun 2021

Digital tool predicts protein stability in a cheaper, safer, and faster way

A cutting-edge digital tool that will make it cheaper, safer and faster for pharmaceutical companies to predict protein stability - a vital step in the development of new medicines - is being rolled out by scientists from the UK's University of Bath through their spin-out company, BLOC Labs.

From University of Bath 31 May 2021

New data shows how exercise improves efficiency of energy production in muscle

Mitochondria are the cell's power plants and produce the majority of a cell's energy needs through an electrochemical process called electron transport chain coupled to another process known as oxidative phosphorylation.

28 May 2021

Neutralizing antibodies are produced after SARS-CoV-2 infection

A research group from Osaka University led by Professor Hisashi Arase and consisting of researchers from the Research Institute for Microbial Diseases, the Institute for Protein Research, the Immunology Frontier Research Center, the Center for Infectious Diseases, and the Graduate School of Medicine has discovered for the first time that both neutralizing antibodies that protect against infection as well as infection-enhancing antibodies that increase infectivity are produced after infection with SARS-CoV-2 by analyzing antibodies derived from COVID-19 patients.

From Osaka University 26 May 2021

Successful class of therapeutics attack and shut down unique and harmful genes

A potential class of therapeutics that uses synthetic nucleic acids to attack and shut down harmful genes while preventing viral spread is gathering momentum.

18 May 2021

Epigenetic changes drive the fate of a B cell

B cells are the immune cells responsible for creating antibodies, and most B cells produce antibodies in response to a pathogen or a vaccine, providing immunity.

14 May 2021

New, patented method helps drugs to easily enter the cells

A new technique known as Progressive Mechanoporation allows genes or drugs to enter cells by mechanically disrupting cell membranes for a brief period.

13 May 2021

Low-dose administration of MERS DNA vaccine protects against COVID-19

The Wistar Institute has developed a synthetic DNA vaccine candidate for Middle East respiratory syndrome coronavirus (MERS-CoV).

26 Apr 2021

New AI model predicts targets for previously unmapped T cells against coronavirus

A research team has created an AI technique that can bind immune cells to their targets and uncouple the types of white blood cells that identify SARS-CoV-2.

26 Apr 2021

Natural molecule can effectively block the binding of human antibodies to SARS-CoV-2

Researchers have found that a natural molecule can effectively block the binding of a subset of human antibodies to SARS-CoV-2. The discovery may help explain why some COVID-19 patients can become severely ill despite having high levels of antibodies against the virus.

23 Apr 2021

SARS-CoV-2 infection produces antibodies that can destroy infected cells

Research teams investigated the antibodies generated in people with symptomatic or asymptomatic SARS-CoV-2 infection.

From Institut Pasteur 23 Apr 2021

Study finds raised levels of specific immune cells in asymptomatic people with COVID-19

The largest study of its type in the UK has identified differences in the immune response to COVID-19, between people with no symptoms, compared to those suffering a more serious reaction to the virus.

21 Apr 2021

Key discovery could prevent treatment failure in people with severe hemophilia A

Recently, researchers achieved a crucial discovery that could mitigate and eliminate immune responses causing treatment failure in people with hemophilia A.

20 Apr 2021

Antibodies may not inhibit SARS-CoV-2 variants from minks

It has been known for about a year that minks can become infected with SARS-CoV-2. The virus had been transmitted from humans to farmed mink and mutated in infected animals. Mutations were acquired in the spike protein, which is crucial for the entry of the virus into host cells and represents the central point of attack for antibodies.

20 Apr 2021

Supercomputer simulations reveal the behavior of dominant G form SARS-CoV-2 strain

Large-scale supercomputer simulations at the atomic level show that the dominant G form variant of the COVID-19-causing virus is more infectious partly because of its greater ability to readily bind to its target host receptor in the body, compared to other variants.

19 Apr 2021

Study reveals how some antibodies can effectively disable ebolaviruses

Some survivors of ebolavirus outbreaks make antibodies that can broadly neutralize these viruses--and now, scientists at Scripps Research have illuminated how these antibodies can disable the viruses so effectively. The insights may be helpful for developing effective therapies.

16 Apr 2021

New fluorescent probe that can discriminate B lymphocytes over T lymphocytes

Human blood contains several different components, including plasma, red blood cells (RBCs), white blood cells (WBCs), and platelets.

15 Apr 2021

Low K777 concentrations inhibit cathepsin L and reduce SARS-CoV-2’s ability to infect host cell lines

For a long time, James McKerrow, MD, PhD, dean of the Skaggs School of Pharmacy and Pharmaceutical Sciences at University of California San Diego, has investigated neglected tropical diseases, which are chronic, disabling parasitic infections mainly affecting the poor and underserved communities in developing nations.

From UC San Diego 5 Apr 2021